Denosumab (DNMB) is an effective treatment for osteoporosis with antiresorptive effect that has demonstrated to increase the bone mass and reduces the incidence of both vertebral and nonvertebral fractures in randomized controlled trials (RCTs).Objectives: To confirm that this drug is actually effective in our experience into daily clinical practice as well.Material and methods: 30 postmenopausal women, mean age 71 years (r</em...
This site uses cookies
Essential cookies
Some cookies are essential and the website may not work correctly without them. These cookies can only be removed by changing your browser preferences.
Other cookies
We use tracking cookies and other non-essential cookies to help improve our services.
We place cookies on your device to give you the best experience of this website. If you don't change your cookie settings, we'll assume you're happy with this.